Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

On September 26, 2025, Onconetix, Inc. and Ocuvex Therapeutics, Inc. jointly announced the termination of their merger agreement, which had originally been established on July 16, 2025. This decision followed extensive discussions and mutual agreement that continuing as independent entities would serve the best interests of both companies and their stakeholders, including patients, partners, and investors.

Anthony Amato, CEO of Ocuvex, emphasized that this termination would not hinder the company's growth or its dedication to patient care. He highlighted that Ocuvex recently secured a New Jersey state pharmaceutical license and is preparing for the upcoming commercial launch of Omlonti, their innovative ophthalmic product. The company's ongoing commitment to advancing its pipeline reinforces their pursuit of breakthroughs in eye health.

Andrew Oakley, Chairman of Onconetix, expressed confidence in Ocuvex’s strong position within the ophthalmic sector. Although the companies are parting ways, he underscored that Omlonti is set to provide significant value to patients and the ophthalmic community.

Both companies expressed gratitude for the collaborative spirit demonstrated during the merger discussions and highlighted their resolve to focus on their respective missions. Onconetix, which specializes in biotechnology solutions for men’s health and oncology, continues to advance innovative products, including Proclarix®, a prostate cancer diagnostic test. Meanwhile, Ocuvex's dedication to ophthalmic science and patient outcomes remains steadfast.

As they navigate their independent futures, both Onconetix and Ocuvex are committed to delivering innovative healthcare solutions, marking a new chapter in their respective journeys. Stakeholders are encouraged to monitor their continued progress as they pursue their individual strategic goals.

The recent mutual termination of the merger agreement between Onconetix, Inc. (Nasdaq: ONCO) and Ocuvex Therapeutics, Inc. is a pivotal moment for both companies and presents an intriguing landscape for investors. This strategic decision underscores the importance of remaining independent to better serve stakeholders and focus on core business areas.

For Onconetix, specializing in innovative solutions for men’s health and oncology, the termination allows the company to hone its efforts on its product pipeline, particularly following the acquisition of Proteomedix and the management of the Proclarix® prostate cancer diagnostic test. Investors should watch for potential updates regarding sales progress in the EU and any strategic partnerships that could amplify growth prospects.

On the other hand, Ocuvex is positioned strongly with the upcoming launch of Omlonti after receiving its New Jersey state pharmaceutical license. The commitment to innovative ophthalmic solutions suggests that the company is on a trajectory for growth, making it an appealing prospect for investors seeking exposure in the ophthalmology sector. Lead effectively by its CEO, Anthony Amato, Ocuvex’s focus remains clear on delivering advanced therapies, maintaining market momentum, and keeping investor interests at the forefront.

Overall, the decision to diverge may intuitively raise questions about potential risks and uncertainties; however, both companies seem resolute in their respective missions. Investors should consider the relative strengths and future potential of each firm independently. Monitoring both companies' market initiatives, financial performance post-announcement, and any strategic partnerships they may enter will be key. For those looking to diversify their portfolios within the biotech and healthcare sectors, both Onconetix and Ocuvex provide unique opportunities, albeit with their specific risk profiles.